<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640168</url>
  </required_header>
  <id_info>
    <org_study_id>20-0006 ACTT-4</org_study_id>
    <nct_id>NCT04640168</nct_id>
  </id_info>
  <brief_title>Adaptive COVID-19 Treatment Trial 4 (ACTT-4)</brief_title>
  <official_title>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone&#xD;
      and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are&#xD;
      discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For&#xD;
      discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain&#xD;
      safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary&#xD;
      research as well as clinical outcome data. However, if infection control or other&#xD;
      restrictions limit the ability of the subject to return to the clinic, these visits may be&#xD;
      conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have&#xD;
      laboratory tests or collection of samples and is conducted by phone. The primary objective is&#xD;
      to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone +&#xD;
      remdesivir as assessed by the mechanical ventilation free survival by Day 29.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an adaptive randomized double-blind placebo-controlled trial to evaluate the&#xD;
      safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with&#xD;
      COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100&#xD;
      sites globally. The study will compare different investigational therapeutic agents to a&#xD;
      control arm. New arms can be introduced according to scientific and public health needs.&#xD;
      There will be interim monitoring to allow early stopping for futility, efficacy, or safety.&#xD;
      If one therapy proves to be efficacious, then this treatment may become the control arm for&#xD;
      comparison(s) with new experimental treatment(s). Any such change would be accompanied by an&#xD;
      updated sample size. This adaptive platform is used to rapidly evaluate different&#xD;
      therapeutics in a population of those hospitalized with moderate to severe COVID-19. The&#xD;
      platform will provide a common framework sharing a similar population, design, endpoints, and&#xD;
      safety oversight. New stages with new therapeutics can be introduced. One independent Data&#xD;
      and Safety Monitoring Board (DSMB) will actively monitor interim data in all stages to make&#xD;
      recommendations about early study closure or changes to study arms.&#xD;
&#xD;
      ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone&#xD;
      and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are&#xD;
      discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For&#xD;
      discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain&#xD;
      safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary&#xD;
      research as well as clinical outcome data. However, if infection control or other&#xD;
      restrictions limit the ability of the subject to return to the clinic, these visits may be&#xD;
      conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have&#xD;
      laboratory tests or collection of samples and is conducted by phone.&#xD;
&#xD;
      All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety&#xD;
      laboratory tests and blood (serum and plasma) research samples and oropharyngeal (OP) swabs&#xD;
      will be obtained on Days 1 (prior to infusion) and Days 3, 5, 8, and 11 (while hospitalized).&#xD;
      OP swabs and blood (serum only) plus safety laboratory tests will be collected on Day 15 and&#xD;
      29 (if the subject attends an in-person visit or are still hospitalized).&#xD;
&#xD;
      The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus&#xD;
      dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.&#xD;
      The key secondary objective is to evaluate the clinical efficacy of baricitinib + remdesivir&#xD;
      versus dexamethasone + remdesivir according to clinical status (8-point ordinal scale) at Day&#xD;
      15.&#xD;
&#xD;
      Contacts:&#xD;
&#xD;
      20-0006 Central Contact&#xD;
&#xD;
      Telephone: 1 (301) 7617948&#xD;
&#xD;
      Email: DMIDClinicalTrials@niaid.nih.gov&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">May 18, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Race</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Ethnicity</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Sex</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-reactive Protein (CRP)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate CRP was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in D-dimer Concentration</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate d-dimer concentration was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prothrombin International Normalized Ratio (INR)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate INR was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cell Count (WBC)</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neutrophils</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils</measure>
    <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
    <description>Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Duration of invasive ventilation/ECMO was measured in days among participants who required invasive ventilation, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Non-invasive Ventilation/High Flow Oxygen</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Duration of supplemental oxygen use was measured in days among participants who were on oxygen at baseline, calculated in two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR) at Day 15</measure>
    <time_frame>Day 1 through Day 15</time_frame>
    <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR) at Day 29</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Discontinuation or Temporary Suspension of Study Product Administration</measure>
    <time_frame>Day 1 through Day 10</time_frame>
    <description>Discontinuation or temporary suspension of study product administration, including participants who died or were discharged, was evaluated for each study product/placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14-day Participant Mortality</measure>
    <time_frame>Day 1 through Day 15</time_frame>
    <description>The mortality rate was determined as the proportion of participants who died by study Day 15. The proportions reported are Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Participant Mortality</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>The mortality rate was determined as the proportion of participants who died by study Day 29. The proportions reported are Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5</measure>
    <time_frame>Day 5</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11</measure>
    <time_frame>Day 11</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories</measure>
    <time_frame>Day 15</time_frame>
    <description>The ordinal scale categories are defined as: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants Not Meeting Criteria for One of the Three Most Severe Ordinal Scale Categories at Any Time.</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>The three most severe ordinal scale categories are: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an Improvement of One Category From Baseline Using an Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least one category was determined for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an Improvement of Two Categories From Baseline Using an Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least two categories was determined for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Day of recovery is defined as the first day on which the participant satisfies one of the following three ordinal scale categories: 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1010</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Remdesivir plus Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remdesivir plus Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.</description>
    <arm_group_label>Remdesivir plus Baricitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.</description>
    <arm_group_label>Remdesivir plus Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching oral baricitinib or intravenous dexamethasone.</description>
    <arm_group_label>Remdesivir plus Baricitinib</arm_group_label>
    <arm_group_label>Remdesivir plus Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.</description>
    <arm_group_label>Remdesivir plus Baricitinib</arm_group_label>
    <arm_group_label>Remdesivir plus Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized with symptoms suggestive of COVID-19.&#xD;
&#xD;
          2. Subject (or legally authorized representative) provides informed consent prior to&#xD;
             initiation of any study procedures and understands and agrees to comply with planned&#xD;
             study procedures.&#xD;
&#xD;
          3. Male or non-pregnant female adult &gt; / = 18 years of age at time of enrollment.&#xD;
&#xD;
          4. Illness of any duration and has laboratory-confirmed SARS-CoV-2 infection as&#xD;
             determined by polymerase chain reaction (PCR) or other commercial or public health&#xD;
             assay (e.g. NAAT, antigen test) in any respiratory specimen or saliva &lt; / = 14 days&#xD;
             prior to randomization.&#xD;
&#xD;
          5. Within the 7 days prior to randomization requiring new use of supplemental oxygen (or&#xD;
             increased oxygen requirement if on chronic oxygen) and requires at the time of&#xD;
             randomization low or high flow oxygen devices or use of non-invasive mechanical&#xD;
             ventilation (ordinal scale category 5 or 6).&#xD;
&#xD;
          6. Women of childbearing potential must agree to either abstinence or use at least one&#xD;
             primary form of contraception not including hormonal contraception from the time of&#xD;
             screening through Day 29.&#xD;
&#xD;
          7. Agrees not to participate in another blinded clinical trial (both pharmacologic and&#xD;
             other types of interventions) for the treatment of COVID-19 through Day 29.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior enrollment in ACTT-3 or ACTT-4. Note: this includes subjects whose participation&#xD;
             in ACTT was terminated early.&#xD;
&#xD;
          2. On invasive mechanical ventilation at the time of randomization (ordinal scale&#xD;
             category 7).&#xD;
&#xD;
          3. Anticipated discharge from the hospital or transfer to another hospital which is not a&#xD;
             study site within 72 hours of randomization.&#xD;
&#xD;
          4. Positive test for influenza virus during the current illness (influenza testing is not&#xD;
             required by protocol).&#xD;
&#xD;
          5. Subjects with a low glomerular filtration rate (eGFR), specifically:&#xD;
&#xD;
               1. Subjects with an eGFR 15-30 mL/min are excluded unless in the opinion of the PI,&#xD;
                  the potential benefit of participation outweighs the potential risk of study&#xD;
                  participation.&#xD;
&#xD;
               2. All subjects with an eGFR &lt;15 mL/min&#xD;
&#xD;
               3. All subjects on hemodialysis and/or hemofiltration at screening, irrespective of&#xD;
                  eGFR are excluded.&#xD;
&#xD;
          6. Neutropenia (absolute neutrophil count &lt;700 cells/microliter, 0.7 x 10^3/microliter).&#xD;
&#xD;
          7. Lymphopenia (absolute lymphocyte count &lt;200 cells/microliter, 0.20 x 10^3/microliter).&#xD;
&#xD;
          8. Received five or more doses of remdesivir including the loading dose, outside of the&#xD;
             study as treatment for COVID-19.&#xD;
&#xD;
          9. Pregnancy or breast feeding (lactating women who agree to discard breast milk from Day&#xD;
             1 until two weeks after the last study product is given are not excluded).&#xD;
&#xD;
         10. Allergy to any study medication.&#xD;
&#xD;
         11. Received convalescent plasma or intravenous immunoglobulin [IVIg] for COVID-19, the&#xD;
             current illness for which they are being enrolled.&#xD;
&#xD;
         12. Received any of the following in the two weeks prior to screening as treatment of&#xD;
             COVID-19:&#xD;
&#xD;
               -  More than one dose of baricitinib for the treatment of COVID-19;&#xD;
&#xD;
               -  Other small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib,&#xD;
                  acalabrutinib, etc.);&#xD;
&#xD;
               -  monoclonal antibodies targeting cytokines (e.g., TNF inhibitors,&#xD;
                  anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], etc.);&#xD;
&#xD;
               -  monoclonal antibodies targeting T-cells or B-cells as treatment for COVID-19.&#xD;
                  Note: receipt of anti-SARS-CoV-2 monoclonal antibody (mAb) prior to enrollment&#xD;
                  (e.g. bamlanivimab) for their current COVID-19 illness is not exclusionary&#xD;
&#xD;
         13. Use of probenecid that cannot be discontinued at study enrollment.&#xD;
&#xD;
         14. Received 6 mg or more of dexamethasone by mouth (po) or Intravenous (IV) (or&#xD;
             equivalent for other glucocorticoids) in one day, on more than one day, in the 7 days&#xD;
             prior to time of randomization. Note: 6 mg dexamethasone dose equivalents include 40&#xD;
             mg prednisone, 32 mg methylprednisolone and 160 mg hydrocortisone.&#xD;
&#xD;
         15. Received &gt; / = 20 mg/day of prednisone po or IV (or equivalent for other&#xD;
             glucocorticoids) for &gt; / = 14 consecutive days in the 4 weeks prior to screening.&#xD;
&#xD;
         16. Have diagnosis of current active or latent tuberculosis (TB), if known, treated for&#xD;
             less than 4 weeks with appropriate therapy (by history only, no screening required).&#xD;
&#xD;
         17. Serious infection (besides COVID-19), immunosuppressive state, or immunosuppressive&#xD;
             medications that in the opinion of the investigator could constitute a risk when&#xD;
             taking baricitinib or dexamethasone.&#xD;
&#xD;
         18. Have received any live vaccine (that is, live attenuated) within 4 weeks before&#xD;
             screening, or intend to receive a live vaccine (or live attenuated) during the study.&#xD;
             Note: Use of non-live (inactivated) vaccinations including SARS-CoV-2 vaccine is&#xD;
             allowed for all subjects.&#xD;
&#xD;
         19. Had a known Venous thromboembolism (VTE)(deep vein thrombosis [DVT] or pulmonary&#xD;
             embolism [PE]) during the current COVID-19 illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine - Infectious Disease</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Fresno Center for Medical Education and Research - Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Health - Jacobs Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>29037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles Medical Center - Westwood Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center - Infectious Disease</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System - Infectious Diseases</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center - Internal Medicine - Infectious Disease</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-1460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego - Infectious Disease Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110-2859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048-1804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Division of Hospital Medicine - Main Campus</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center - Division of Infectious Diseases</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health - Jacksonville - Department of Emergency Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine - Infectious Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Vaccine Center - The Hope Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center - Infectious Diseases Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Hospital - Infectious Disease</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago College of Medicine - Division of Infectious Diseases</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics - Department of Internal Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine - Center for Vaccine Development - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital - Medicine - Infectious Diseases</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School - Infectious Diseases and Immunology</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan - Infectious Disease Clinic at Taubman Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University - Center for Vaccine Development</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center - Infectious Diseases</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Creighton University Medical Center - Bergan Mercy - Pulmonary Medicine</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Clinical and Translational Science Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Infectious Diseases</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center - Vaccine Research Unit</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Human Vaccine Institute - Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womack Army Medical Center - Pulmonary and Respiratory Services</name>
      <address>
        <city>Fort Bragg</city>
        <state>North Carolina</state>
        <zip>28310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center - Surgery</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest - Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania - Infectious Diseases</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh - Medicine - Infectious Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch - Division of Infectious Disease</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Molecular Virology and Microbiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio - Infectious Diseases</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Infectious Diseases</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia - Acute Care Surgery</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth - Infectious Disease Division</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EvergreenHealth Infectious Disease Service</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Infectious Disease Clinic</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University - Medical Hospital - Department of Respiratory Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital - Division of Infectious Diseases</name>
      <address>
        <city>Bundang-gu Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricin Salvador Zubirn - Departamento de Infectologia</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Coso Villegas</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Health System - Division of Infectious Diseases</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Health System - Alexandra Hospital - Division of Infectious Diseases</name>
      <address>
        <city>Singapore</city>
        <zip>159964</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Centre for Infectious Diseases</name>
      <address>
        <city>Singapore</city>
        <zip>308442</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital - Clinical Trials and Research Unit (CTRU)</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ng Teng Fong General Hospital - Infectious Disease Service</name>
      <address>
        <city>Singapore</city>
        <zip>609606</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Indonesia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <results_first_submitted>April 14, 2022</results_first_submitted>
  <results_first_submitted_qc>June 22, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2022</results_first_posted>
  <last_update_submitted>June 22, 2022</last_update_submitted>
  <last_update_submitted_qc>June 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACTT</keyword>
  <keyword>Adaptive</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Multicenter</keyword>
  <keyword>novel coronavirus</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04640168/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the participating sites from those admitted with symptoms of COVID-19 confirmed by PCR. Enrollment occurred between December 2, 2020 and April 13, 2021.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Remdesivir Plus Baricitinib</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.&#xD;
Baricitinib: Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.&#xD;
Placebo: Placebo matching intravenous dexamethasone.&#xD;
Remdesivir: Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.</description>
        </group>
        <group group_id="P2">
          <title>Remdesivir Plus Dexamethasone</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.&#xD;
Dexamethasone: Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.&#xD;
Placebo: Placebo matching oral baricitinib.&#xD;
Remdesivir: Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT and Modified ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>As Treated Population</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="495"/>
                <participants group_id="P2" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled but not treated</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The population includes all participants enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Remdesivir Plus Baricitinib</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
        </group>
        <group group_id="B2">
          <title>Remdesivir Plus Dexamethasone</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="516"/>
            <count group_id="B2" value="494"/>
            <count group_id="B3" value="1010"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="675"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="14.3"/>
                    <measurement group_id="B2" value="58.5" spread="13.7"/>
                    <measurement group_id="B3" value="58.3" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="347"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="636"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="588"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="474"/>
                    <measurement group_id="B2" value="453"/>
                    <measurement group_id="B3" value="927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)</title>
        <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)</title>
          <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.84" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.84" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT)</title>
        <description>Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT)</title>
          <description>Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>Units/Liter (U/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="483"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.9" upper_limit="3.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0.8" upper_limit="11.2"/>
                    <measurement group_id="O2" value="15.9" lower_limit="11.6" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="-5.9" upper_limit="15.3"/>
                    <measurement group_id="O2" value="16.1" lower_limit="2.6" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="-2.0" upper_limit="13.2"/>
                    <measurement group_id="O2" value="15.5" lower_limit="4.1" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="-1.1" upper_limit="15.2"/>
                    <measurement group_id="O2" value="8.2" lower_limit="-3.3" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-16.3" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-26.3" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST)</title>
        <description>Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST)</title>
          <description>Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="482"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" lower_limit="-8.1" upper_limit="-3.6"/>
                    <measurement group_id="O2" value="-7.2" lower_limit="-12.8" upper_limit="-1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-11.9" upper_limit="3.9"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-13.1" upper_limit="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" lower_limit="-19.8" upper_limit="-1.8"/>
                    <measurement group_id="O2" value="-12.0" lower_limit="-27.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" lower_limit="-19.4" upper_limit="-4.9"/>
                    <measurement group_id="O2" value="-16.4" lower_limit="-23.0" upper_limit="-9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" lower_limit="-19.9" upper_limit="-6.8"/>
                    <measurement group_id="O2" value="-15.4" lower_limit="-20.8" upper_limit="-10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" lower_limit="-23.8" upper_limit="-13.4"/>
                    <measurement group_id="O2" value="9.9" lower_limit="-53.3" upper_limit="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-reactive Protein (CRP)</title>
        <description>Blood to evaluate CRP was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The mITT population includes all participants by their randomized treatment assignment and baseline ordinal score. For missing data, if results were available for visits before or after that visit, the average of the two nearest visits was imputed. If a participant died or was lost to follow-up, their last available observation was carried forward. If baseline was missing, the earliest post-treatment dose was used. Participants from sites reporting high sensitivity CRP were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein (CRP)</title>
          <description>Blood to evaluate CRP was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The mITT population includes all participants by their randomized treatment assignment and baseline ordinal score. For missing data, if results were available for visits before or after that visit, the average of the two nearest visits was imputed. If a participant died or was lost to follow-up, their last available observation was carried forward. If baseline was missing, the earliest post-treatment dose was used. Participants from sites reporting high sensitivity CRP were excluded.</population>
          <units>milligrams/liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.1" lower_limit="-46.6" upper_limit="-35.5"/>
                    <measurement group_id="O2" value="-61.0" lower_limit="-66.9" upper_limit="-55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.4" lower_limit="-46.0" upper_limit="-32.8"/>
                    <measurement group_id="O2" value="-73.6" lower_limit="-80.1" upper_limit="-67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.0" lower_limit="-60.3" upper_limit="-45.7"/>
                    <measurement group_id="O2" value="-79.0" lower_limit="-86.1" upper_limit="-72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.6" lower_limit="-69.2" upper_limit="-54.1"/>
                    <measurement group_id="O2" value="-81.6" lower_limit="-88.9" upper_limit="-74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.2" lower_limit="-80.8" upper_limit="-65.7"/>
                    <measurement group_id="O2" value="-81.1" lower_limit="-88.7" upper_limit="-73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.6" lower_limit="-86.2" upper_limit="-70.9"/>
                    <measurement group_id="O2" value="-84.1" lower_limit="-91.8" upper_limit="-76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine</title>
        <description>Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine</title>
          <description>Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="484"/>
                    <count group_id="O2" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.207" lower_limit="-0.521" upper_limit="0.108"/>
                    <measurement group_id="O2" value="-0.081" lower_limit="-0.102" upper_limit="-0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.287" lower_limit="-0.701" upper_limit="0.127"/>
                    <measurement group_id="O2" value="-0.122" lower_limit="-0.147" upper_limit="-0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.434" lower_limit="-1.175" upper_limit="0.308"/>
                    <measurement group_id="O2" value="-0.096" lower_limit="-0.132" upper_limit="-0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.121" upper_limit="0.135"/>
                    <measurement group_id="O2" value="-0.102" lower_limit="-0.165" upper_limit="-0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" lower_limit="-0.101" upper_limit="0.080"/>
                    <measurement group_id="O2" value="-0.024" lower_limit="-0.086" upper_limit="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" lower_limit="-0.100" upper_limit="-0.029"/>
                    <measurement group_id="O2" value="-0.029" lower_limit="-0.090" upper_limit="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in D-dimer Concentration</title>
        <description>Blood to evaluate d-dimer concentration was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The mITT population includes all participants by their randomized treatment assignment and baseline ordinal score. For any missing data, if results were available for visits before or after that visit, the average of the two nearest visits was imputed for all missing visits between them. If a participant died or was lost to follow-up, their last available observation was carried forward. If baseline was missing, another pre-treatment dose was used, or the earliest post-treatment dose was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in D-dimer Concentration</title>
          <description>Blood to evaluate d-dimer concentration was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The mITT population includes all participants by their randomized treatment assignment and baseline ordinal score. For any missing data, if results were available for visits before or after that visit, the average of the two nearest visits was imputed for all missing visits between them. If a participant died or was lost to follow-up, their last available observation was carried forward. If baseline was missing, another pre-treatment dose was used, or the earliest post-treatment dose was used.</population>
          <units>mg/L fibrinogen-equivalent units (FEU)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="490"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.2" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.2" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-0.1" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose</title>
        <description>Blood to evaluate glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose</title>
          <description>Blood to evaluate glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="484"/>
                    <count group_id="O2" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.9" lower_limit="-53.0" upper_limit="-40.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="-2.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.2" lower_limit="-50.9" upper_limit="-35.5"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-14.9" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" lower_limit="-45.5" upper_limit="-24.4"/>
                    <measurement group_id="O2" value="-9.6" lower_limit="-22.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" lower_limit="-43.2" upper_limit="-13.0"/>
                    <measurement group_id="O2" value="-15.0" lower_limit="-30.6" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" lower_limit="-35.3" upper_limit="-16.6"/>
                    <measurement group_id="O2" value="-20.2" lower_limit="-31.3" upper_limit="-9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" lower_limit="-38.8" upper_limit="-19.0"/>
                    <measurement group_id="O2" value="-25.4" lower_limit="-36.1" upper_limit="-14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin</title>
        <description>Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin</title>
          <description>Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>grams/deciliter (g/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="481"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" lower_limit="-0.59" upper_limit="-0.43"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-0.35" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-0.80" upper_limit="-0.47"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-0.25" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-1.28" upper_limit="-0.88"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-0.37" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" lower_limit="-1.75" upper_limit="-1.13"/>
                    <measurement group_id="O2" value="-0.76" lower_limit="-1.03" upper_limit="-0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-1.23" upper_limit="-0.71"/>
                    <measurement group_id="O2" value="-0.91" lower_limit="-1.13" upper_limit="-0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" lower_limit="-0.75" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-0.93" upper_limit="-0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets</title>
        <description>Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets</title>
          <description>Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="479"/>
                    <count group_id="O2" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="48.6" upper_limit="57.5"/>
                    <measurement group_id="O2" value="70.4" lower_limit="65.6" upper_limit="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.4" lower_limit="98.8" upper_limit="116.0"/>
                    <measurement group_id="O2" value="117.6" lower_limit="108.9" upper_limit="126.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.9" lower_limit="161.4" upper_limit="196.3"/>
                    <measurement group_id="O2" value="140.4" lower_limit="125.7" upper_limit="155.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.9" lower_limit="166.5" upper_limit="221.3"/>
                    <measurement group_id="O2" value="105.0" lower_limit="86.7" upper_limit="123.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" lower_limit="119.0" upper_limit="160.3"/>
                    <measurement group_id="O2" value="45.3" lower_limit="29.4" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="22.8" upper_limit="47.8"/>
                    <measurement group_id="O2" value="69.4" lower_limit="56.1" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Prothrombin International Normalized Ratio (INR)</title>
        <description>Blood to evaluate INR was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Prothrombin International Normalized Ratio (INR)</title>
          <description>Blood to evaluate INR was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.04" upper_limit="0.09"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.08" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.09" upper_limit="0.13"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.13" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.08" upper_limit="0.14"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.25" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.03" upper_limit="0.14"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.42" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.03" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.08" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.09" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.08" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin</title>
        <description>Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin</title>
          <description>Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="482"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.02" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.11" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.06" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.01" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.01" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.03" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.01" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.06" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.02" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.05" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.10" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cell Count (WBC)</title>
        <description>Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cell Count (WBC)</title>
          <description>Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="481"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="458"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.433" lower_limit="0.196" upper_limit="0.670"/>
                    <measurement group_id="O2" value="1.292" lower_limit="1.054" upper_limit="1.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.358" lower_limit="1.006" upper_limit="1.709"/>
                    <measurement group_id="O2" value="2.072" lower_limit="1.712" upper_limit="2.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.629" lower_limit="1.946" upper_limit="3.311"/>
                    <measurement group_id="O2" value="4.048" lower_limit="3.415" upper_limit="4.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.153" lower_limit="3.098" upper_limit="5.209"/>
                    <measurement group_id="O2" value="5.179" lower_limit="4.177" upper_limit="6.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.638" lower_limit="0.965" upper_limit="2.310"/>
                    <measurement group_id="O2" value="2.386" lower_limit="1.697" upper_limit="3.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.688" lower_limit="0.103" upper_limit="1.273"/>
                    <measurement group_id="O2" value="0.116" lower_limit="-0.468" upper_limit="0.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neutrophils</title>
        <description>Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neutrophils</title>
          <description>Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="477"/>
                    <count group_id="O2" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.500" lower_limit="-0.721" upper_limit="-0.280"/>
                    <measurement group_id="O2" value="0.974" lower_limit="0.749" upper_limit="1.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.356" lower_limit="0.007" upper_limit="0.704"/>
                    <measurement group_id="O2" value="1.407" lower_limit="1.076" upper_limit="1.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.421" lower_limit="0.763" upper_limit="2.080"/>
                    <measurement group_id="O2" value="3.227" lower_limit="2.621" upper_limit="3.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.937" lower_limit="1.935" upper_limit="3.940"/>
                    <measurement group_id="O2" value="4.135" lower_limit="3.177" upper_limit="5.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.416" lower_limit="-0.216" upper_limit="1.047"/>
                    <measurement group_id="O2" value="1.229" lower_limit="0.560" upper_limit="1.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.659" lower_limit="-1.227" upper_limit="-0.092"/>
                    <measurement group_id="O2" value="-1.239" lower_limit="-1.801" upper_limit="-0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes</title>
        <description>Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes</title>
          <description>Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="477"/>
                    <count group_id="O2" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.766" lower_limit="0.678" upper_limit="0.854"/>
                    <measurement group_id="O2" value="0.142" lower_limit="0.100" upper_limit="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.627" lower_limit="0.559" upper_limit="0.696"/>
                    <measurement group_id="O2" value="0.356" lower_limit="0.293" upper_limit="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.614" lower_limit="0.517" upper_limit="0.712"/>
                    <measurement group_id="O2" value="0.317" lower_limit="0.231" upper_limit="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.594" lower_limit="0.462" upper_limit="0.727"/>
                    <measurement group_id="O2" value="0.372" lower_limit="0.275" upper_limit="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.693" lower_limit="0.599" upper_limit="0.788"/>
                    <measurement group_id="O2" value="0.621" lower_limit="0.536" upper_limit="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" lower_limit="0.650" upper_limit="1.033"/>
                    <measurement group_id="O2" value="0.996" lower_limit="0.900" upper_limit="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes</title>
        <description>Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes</title>
          <description>Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="477"/>
                    <count group_id="O2" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.114" lower_limit="0.090" upper_limit="0.138"/>
                    <measurement group_id="O2" value="0.120" lower_limit="0.096" upper_limit="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" lower_limit="0.133" upper_limit="0.195"/>
                    <measurement group_id="O2" value="0.180" lower_limit="0.148" upper_limit="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.257" lower_limit="0.208" upper_limit="0.306"/>
                    <measurement group_id="O2" value="0.221" lower_limit="0.174" upper_limit="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.367" lower_limit="0.283" upper_limit="0.452"/>
                    <measurement group_id="O2" value="0.306" lower_limit="0.228" upper_limit="0.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.295" lower_limit="0.246" upper_limit="0.344"/>
                    <measurement group_id="O2" value="0.286" lower_limit="0.232" upper_limit="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.171" lower_limit="0.133" upper_limit="0.209"/>
                    <measurement group_id="O2" value="0.159" lower_limit="0.121" upper_limit="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils</title>
        <description>Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils</title>
          <description>Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="471"/>
                <count group_id="O2" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="0.005" upper_limit="0.011"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.003" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" lower_limit="0.011" upper_limit="0.020"/>
                    <measurement group_id="O2" value="0.004" lower_limit="0.001" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" lower_limit="0.011" upper_limit="0.020"/>
                    <measurement group_id="O2" value="0.006" lower_limit="0.002" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" lower_limit="0.014" upper_limit="0.027"/>
                    <measurement group_id="O2" value="0.006" lower_limit="0.000" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.029" upper_limit="0.041"/>
                    <measurement group_id="O2" value="0.030" lower_limit="0.021" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" lower_limit="0.035" upper_limit="0.051"/>
                    <measurement group_id="O2" value="0.046" lower_limit="0.033" upper_limit="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils</title>
        <description>Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
        <time_frame>Days 1, 3, 5, 8, 11, 15 and 29</time_frame>
        <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils</title>
          <description>Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.</description>
          <population>The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.</population>
          <units>10^9 cells/liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="472"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" lower_limit="0.029" upper_limit="0.040"/>
                    <measurement group_id="O2" value="-0.006" lower_limit="-0.009" upper_limit="-0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" lower_limit="0.092" upper_limit="0.116"/>
                    <measurement group_id="O2" value="0.006" lower_limit="0.002" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" lower_limit="0.100" upper_limit="0.131"/>
                    <measurement group_id="O2" value="0.027" lower_limit="0.016" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" lower_limit="0.089" upper_limit="0.143"/>
                    <measurement group_id="O2" value="0.034" lower_limit="0.020" upper_limit="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.124" lower_limit="0.108" upper_limit="0.141"/>
                    <measurement group_id="O2" value="0.119" lower_limit="0.102" upper_limit="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.208" lower_limit="0.179" upper_limit="0.238"/>
                    <measurement group_id="O2" value="0.211" lower_limit="0.169" upper_limit="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)</title>
        <description>Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The safety population includes all participants with available data post baseline, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)</title>
          <description>Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.</description>
          <population>The safety population includes all participants with available data post baseline, analyzed as treated.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Serious Adverse Events (SAEs)</title>
        <description>An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The safety population includes all participants with available data post baseline, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Serious Adverse Events (SAEs)</title>
          <description>An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.</description>
          <population>The safety population includes all participants with available data post baseline, analyzed as treated.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO)</title>
        <description>Duration of invasive ventilation/ECMO was measured in days among participants who required invasive ventilation, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The analysis population is restricted to randomized participants who were on invasive ventilation.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO)</title>
          <description>Duration of invasive ventilation/ECMO was measured in days among participants who required invasive ventilation, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
          <population>The analysis population is restricted to randomized participants who were on invasive ventilation.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Including imputations for participants who died</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="14" upper_limit="28"/>
                    <measurement group_id="O2" value="28" lower_limit="18" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among participants who did not die</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Non-invasive Ventilation/High Flow Oxygen</title>
        <description>Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The analysis population is restricted to randomized participants who were not on noninvasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Non-invasive Ventilation/High Flow Oxygen</title>
          <description>Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
          <population>The analysis population is restricted to randomized participants who were not on noninvasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Including imputations for participants who died</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among participants who did not die</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Supplemental Oxygen Use</title>
        <description>Duration of supplemental oxygen use was measured in days among participants who were on oxygen at baseline, calculated in two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The analysis population is restricted to randomized participants who were on oxygen at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen Use</title>
          <description>Duration of supplemental oxygen use was measured in days among participants who were on oxygen at baseline, calculated in two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
          <population>The analysis population is restricted to randomized participants who were on oxygen at baseline.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Including imputations for participants who died</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="515"/>
                    <count group_id="O2" value="494"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="O2" value="10.5" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among participants who did not die</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desirability of Outcome Ranking (DOOR) at Day 15</title>
        <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
        <time_frame>Day 1 through Day 15</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability of Outcome Ranking (DOOR) at Day 15</title>
          <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 - Recovered (Category 1, 2 or 3 Clinical Status)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="71.8" upper_limit="79.2"/>
                    <measurement group_id="O2" value="77" lower_limit="73.0" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Improved (=1 category improvement in Clinical Status compared with baseline) &amp; no SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="1" lower_limit="0.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Improved (=1 category improvement compared with baseline) &amp; SAE (related or unrelated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2" lower_limit="1.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - No change in Clinical Status from baseline &amp; no SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5.3" upper_limit="9.7"/>
                    <measurement group_id="O2" value="6" lower_limit="4.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - No change in Clinical Status from baseline &amp; SAE (related or unrelated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.2" upper_limit="5.5"/>
                    <measurement group_id="O2" value="2" lower_limit="1.1" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Worsening (=1 category worse in Clinical Status compared with baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4.9" upper_limit="9.3"/>
                    <measurement group_id="O2" value="10" lower_limit="7.2" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.9" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3" lower_limit="1.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desirability of Outcome Ranking (DOOR) at Day 29</title>
        <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability of Outcome Ranking (DOOR) at Day 29</title>
          <description>Desirability of Outcome Ranking (DOOR) based on ordinal scale: 1) Recovered (category 1, 2 or 3 on ordinal scale); 2) Improved (&gt; / = 1 category improvement of ordinal scale compared with baseline) &amp; no serious adverse event (SAE); 3) Improved (&gt; / = 1 category improvement of the ordinal scale compared with baseline) &amp; SAE (related or unrelated); 4) No change in ordinal scale from baseline &amp; no SAE; 5) No change in ordinal scale from baseline &amp; SAE (related or unrelated); 6) Worsening (&gt; / = 1 category worse in ordinal scale from baseline); 7) Death.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 - Recovered (Category 1, 2 or 3 Clinical Status)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="81.5" upper_limit="87.7"/>
                    <measurement group_id="O2" value="84" lower_limit="80.5" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Improved (=1 category improvement in Clinical Status compared with baseline) &amp; no SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="0.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.002" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Improved (=1 category improvement compared with baseline) &amp; SAE (related or unrelated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1" lower_limit="0.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - No change in Clinical Status from baseline &amp; no SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.1" upper_limit="5.2"/>
                    <measurement group_id="O2" value="3" lower_limit="2.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - No change in Clinical Status from baseline &amp; SAE (related or unrelated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1" lower_limit="0.2" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Worsening (=1 category worse in Clinical Status compared with baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.2" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4" lower_limit="2.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3.8" upper_limit="7.7"/>
                    <measurement group_id="O2" value="7" lower_limit="5.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intent-to-treat (ITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.</description>
          <population>The modified intent-to-treat (ITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Including imputations for participants who died</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="515"/>
                    <count group_id="O2" value="494"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among participants who did not die</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Discontinuation or Temporary Suspension of Study Product Administration</title>
        <description>Discontinuation or temporary suspension of study product administration, including participants who died or were discharged, was evaluated for each study product/placebo.</description>
        <time_frame>Day 1 through Day 10</time_frame>
        <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Discontinuation or Temporary Suspension of Study Product Administration</title>
          <description>Discontinuation or temporary suspension of study product administration, including participants who died or were discharged, was evaluated for each study product/placebo.</description>
          <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remdesivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baricitinib/Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486"/>
                    <measurement group_id="O2" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dexamethasone/placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410"/>
                    <measurement group_id="O2" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>14-day Participant Mortality</title>
        <description>The mortality rate was determined as the proportion of participants who died by study Day 15. The proportions reported are Kaplan-Meier estimates.</description>
        <time_frame>Day 1 through Day 15</time_frame>
        <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>14-day Participant Mortality</title>
          <description>The mortality rate was determined as the proportion of participants who died by study Day 15. The proportions reported are Kaplan-Meier estimates.</description>
          <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.02" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Participant Mortality</title>
        <description>The mortality rate was determined as the proportion of participants who died by study Day 29. The proportions reported are Kaplan-Meier estimates.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Participant Mortality</title>
          <description>The mortality rate was determined as the proportion of participants who died by study Day 29. The proportions reported are Kaplan-Meier estimates.</description>
          <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.04" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 1</time_frame>
        <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The mITT population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="13.2" upper_limit="19.5"/>
                    <measurement group_id="O2" value="14.2" lower_limit="11.4" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" lower_limit="80.3" upper_limit="86.6"/>
                    <measurement group_id="O2" value="85.8" lower_limit="82.5" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 3</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.9" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="18.8" upper_limit="25.9"/>
                    <measurement group_id="O2" value="21.5" lower_limit="18.1" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="67.6" upper_limit="75.4"/>
                    <measurement group_id="O2" value="73.5" lower_limit="69.4" upper_limit="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.6" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 5</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.6" upper_limit="7.5"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="16.2" upper_limit="23.1"/>
                    <measurement group_id="O2" value="20.9" lower_limit="17.5" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" lower_limit="49.1" upper_limit="57.7"/>
                    <measurement group_id="O2" value="49.2" lower_limit="44.8" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="7.3" upper_limit="12.4"/>
                    <measurement group_id="O2" value="11.9" lower_limit="9.4" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.3" upper_limit="13.6"/>
                    <measurement group_id="O2" value="13.2" lower_limit="10.5" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 8</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="5.4" upper_limit="10.0"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="9.7" upper_limit="15.3"/>
                    <measurement group_id="O2" value="14.6" lower_limit="11.7" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" lower_limit="21.3" upper_limit="28.8"/>
                    <measurement group_id="O2" value="24.5" lower_limit="20.9" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.6" upper_limit="8.9"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.7" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="42.1" upper_limit="50.7"/>
                    <measurement group_id="O2" value="47.0" lower_limit="42.6" upper_limit="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 11</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="5.8" upper_limit="10.4"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="4.8" upper_limit="9.1"/>
                    <measurement group_id="O2" value="9.1" lower_limit="6.9" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.7" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.6" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="59.3" upper_limit="67.5"/>
                    <measurement group_id="O2" value="66.4" lower_limit="62.1" upper_limit="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.8" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 15</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.9" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="4.4" upper_limit="8.6"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.4" upper_limit="5.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="7.1" upper_limit="12.1"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.8" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.4" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="47.1" upper_limit="55.7"/>
                    <measurement group_id="O2" value="53.6" lower_limit="49.2" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="19.9" upper_limit="27.1"/>
                    <measurement group_id="O2" value="22.9" lower_limit="19.4" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 22</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.3" upper_limit="7.1"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.3" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.8" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.3" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.7" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.8" upper_limit="7.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.8" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="43.7" upper_limit="52.3"/>
                    <measurement group_id="O2" value="48.0" lower_limit="43.6" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="30.6" upper_limit="38.8"/>
                    <measurement group_id="O2" value="33.6" lower_limit="29.6" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, participant is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.8" upper_limit="7.7"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.6" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.3" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.7" upper_limit="6.2"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or need for oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="53.0" upper_limit="61.5"/>
                    <measurement group_id="O2" value="52.0" lower_limit="47.6" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="23.9" upper_limit="31.6"/>
                    <measurement group_id="O2" value="32.0" lower_limit="28.0" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories</title>
        <description>The ordinal scale categories are defined as: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 15</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories</title>
          <description>The ordinal scale categories are defined as: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8) Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.9" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3" lower_limit="1." upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Hospitalized, on invasive mechanical ventilation or ECMO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4.4" upper_limit="8.6"/>
                    <measurement group_id="O2" value="6" lower_limit="4.3" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Hospitalized, on non-invasive ventilation or high flow oxygen devices</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2.4" upper_limit="5.7"/>
                    <measurement group_id="O2" value="5" lower_limit="3.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Hospitalized, requiring supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7.1" upper_limit="12.1"/>
                    <measurement group_id="O2" value="8" lower_limit="5.8" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.1" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1" lower_limit="0.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.4" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Not hospitalized, but has new or increased limitation on activities and/or new oxygen use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="47.1" upper_limit="55.7"/>
                    <measurement group_id="O2" value="54" lower_limit="49.2" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Not hospitalized, no limitations on activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19.9" upper_limit="27.1"/>
                    <measurement group_id="O2" value="23" lower_limit="19.4" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Participants Not Meeting Criteria for One of the Three Most Severe Ordinal Scale Categories at Any Time.</title>
        <description>The three most severe ordinal scale categories are: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Not Meeting Criteria for One of the Three Most Severe Ordinal Scale Categories at Any Time.</title>
          <description>The three most severe ordinal scale categories are: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.77" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.78" lower_limit="0.74" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to an Improvement of One Category From Baseline Using an Ordinal Scale</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least one category was determined for each participant.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to an Improvement of One Category From Baseline Using an Ordinal Scale</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least one category was determined for each participant.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to an Improvement of Two Categories From Baseline Using an Ordinal Scale</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least two categories was determined for each participant.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to an Improvement of Two Categories From Baseline Using an Ordinal Scale</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use. Time to improvement by at least two categories was determined for each participant.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery</title>
        <description>Day of recovery is defined as the first day on which the participant satisfies one of the following three ordinal scale categories: 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery</title>
          <description>Day of recovery is defined as the first day on which the participant satisfies one of the following three ordinal scale categories: 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care; 2) Not hospitalized, but has new or increased limitation on activities and/or new or increased requirement for home oxygen over baseline, pre-COVID-19 status; 1) Not hospitalized, patient is back to their baseline, pre-COVID-19 status, that is, no new or increased limitations on activities and no new or increased oxygen use.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized, classified by their randomized treatment assignment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Race</title>
        <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Race</title>
          <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.58" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.71" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.83" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.77" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.82" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.83" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.78" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.80" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Ethnicity</title>
        <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized and for whom ethnicity was reported. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Ethnicity</title>
          <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized and for whom ethnicity was reported. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.82" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.83" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.82" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.81" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Sex</title>
        <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Remdesivir Plus Baricitinib</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
          <group group_id="O2">
            <title>Remdesivir Plus Dexamethasone</title>
            <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Sex</title>
          <description>Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO as of Day 29. Results are reported as Kaplan Meier estimates.</description>
          <population>The modified intention-to-treat (mITT) population includes all participants who were randomized. mITT participants were classified by their randomized treatment assignment and their baseline ordinal score, which is not necessarily equivalent to the disease severity stratum to which the participant was randomized at enrollment. One participant was excluded from mITT analyses due to a baseline ordinal score of 4.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.81" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.83" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.84" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.82" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and Grade 3 and 4 non-serious adverse events were collected for 29 days after the first dose. Laboratory values were systematically assessed at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29. Treatment emergent and fatal AEs are reported.</time_frame>
      <desc>Given the severity of underlying illness, participants were expected to have many symptoms and abnormalities in vital signs and laboratory values. All Grade 3 and 4 AEs were captured as AEs in this trial.&#xD;
Grade 2 or higher, suspected drug-related hypersensitivity reaction or deep vein thrombosis or pulmonary embolism of any grade was reported as an AE in this trial. All cause mortality was calculated for the ITT population, while SAEs and AEs reflect the as treated population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Remdesivir Plus Baricitinib</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
        </group>
        <group group_id="E2">
          <title>Remdesivir Plus Dexamethasone</title>
          <description>200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="516"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="494"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="503"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="503"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="503"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Substance use disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="503"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="503"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="503"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="503"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="503"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="503"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="503"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Beigel, MD</name_or_title>
      <organization>NIAID</organization>
      <phone>3014519881</phone>
      <email>jbeigel@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

